Skip to main content
Journal cover image

A Phase 1 Trial of Valemetostat in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)

Publication ,  Conference
Erba, HP; Oluwole, OO; Bixby, D; Rampal, RK; Fathi, AT; Paliwal, P; Jin, J; Inoue, A; Daver, N
Published in: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
2024

Duke Scholars

Published In

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

EISSN

2152-2669

ISSN

2152-2650

Publication Date

2024

Volume

24

Start / End Page

S311 / S312

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3201 Cardiovascular medicine and haematology
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Erba, H. P., Oluwole, O. O., Bixby, D., Rampal, R. K., Fathi, A. T., Paliwal, P., … Daver, N. (2024). A Phase 1 Trial of Valemetostat in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Acute Lymphocytic Leukemia (ALL). In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (Vol. 24, pp. S311–S312).
Erba, Harry P., Olalekan O. Oluwole, Dale Bixby, Raajit K. Rampal, Amir T. Fathi, Prashni Paliwal, Jin Jin, Ai Inoue, and Naval Daver. “A Phase 1 Trial of Valemetostat in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Acute Lymphocytic Leukemia (ALL).” In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 24:S311–12, 2024.
Erba HP, Oluwole OO, Bixby D, Rampal RK, Fathi AT, Paliwal P, et al. A Phase 1 Trial of Valemetostat in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Acute Lymphocytic Leukemia (ALL). In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2024. p. S311–2.
Erba, Harry P., et al. “A Phase 1 Trial of Valemetostat in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Acute Lymphocytic Leukemia (ALL).” CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol. 24, 2024, pp. S311–12.
Erba HP, Oluwole OO, Bixby D, Rampal RK, Fathi AT, Paliwal P, Jin J, Inoue A, Daver N. A Phase 1 Trial of Valemetostat in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Acute Lymphocytic Leukemia (ALL). CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. 2024. p. S311–S312.
Journal cover image

Published In

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

EISSN

2152-2669

ISSN

2152-2650

Publication Date

2024

Volume

24

Start / End Page

S311 / S312

Related Subject Headings

  • 3211 Oncology and carcinogenesis
  • 3201 Cardiovascular medicine and haematology
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences